Molecular pathology of non-small cell carcinoma

被引:11
|
作者
Yatabe, Yasushi [1 ,2 ]
机构
[1] Natl Canc Ctr, Dept Diagnost Pathol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Diagnost Pathol, 5-1-1 Tsukiji, Chuo Ku, Tokyo 1040045, Japan
基金
日本学术振兴会;
关键词
immune check-point inhibitors; lung cancer; molecular pathogenesis; oncogene addiction; two-compartment model; FACTOR-RECEPTOR GENE; IMMUNE CHECKPOINT INHIBITORS; TUMOR MUTATION BURDEN; LUNG-CANCER; EGFR MUTATIONS; TYROSINE KINASE; CLINICOPATHOLOGICAL FEATURES; RET REARRANGEMENTS; CLINICAL-FEATURES; PD-L1; EXPRESSION;
D O I
10.1111/his.15080
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Currently, lung cancer is treated by the highest number of therapeutic options and the benefits are based on multiple large-scale sequencing studies, translational research and new drug development, which has promoted our understanding of the molecular pathology of lung cancer. According to the driver alterations, different characteristics have been revealed, such as differences in ethnic prevalence, median age and alteration patterns. Consequently, beyond traditional chemoradiotherapy, molecular-targeted therapy and treatment with immune check-point inhibitors (ICI) also became available major therapeutic options. Interestingly, clinical results suggest that the recently established therapies target distinct lung cancer proportions, particularly between the EGFR/ALK and PD-1/PD-L1-positive subsets, e.g. the kinase inhibitors target driver mutation-positive tumours, whereas driver mutation-negative tumours respond to ICI treatment. These therapeutic efficacy-related differences might be explained by the molecular pathogenesis of lung cancer. Addictive driver mutations promote tumour formation with powerful transformation performance, resulting in a low tumour mutation burden, reduced immune surveillance, and subsequent poor response to ICIs. In contrast, regular tobacco smoke exposure repeatedly injures the proximal airway epithelium, leading to accumulated genetic alterations. In the latter pathway, overgrowth due to alteration and immunological exclusion against neoantigens is initially balanced. However, tumours could be generated from certain clones that outcompete immunological exclusion and outgrow the others. Consequently, this cancer type responds to immune check-point treatment. These pathogenic differences are explained well by the two-compartment model, focusing upon the anatomical and functional composition of distinct cellular components between the terminal respiratory unit and the air-conducting system. Two-compartment model in the putative molecular pathogenesis of lung cancer. The accumulation of genetic alterations with escaping immune surveillance is a key factor for tumours from the air-conducting system under the strong influence of tobacco smoke, whereas oncogene-addicted adenocarcinomas are driven by a single oncogenic mutation with powerful transformation activity.image
引用
收藏
页码:50 / 66
页数:17
相关论文
共 50 条
  • [1] Current concepts on the molecular pathology of non-small cell lung carcinoma
    Fujimoto, Junya
    Wistuba, Ignacio I.
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2014, 31 (04) : 306 - 313
  • [2] Pathology and molecular pathology of non-small cell lung cancer
    Junker, K.
    PNEUMOLOGE, 2015, 12 (01): : 9 - 18
  • [3] THE PATHOLOGY OF NON-SMALL CELL-CARCINOMA OF THE LUNG
    MATTHEWS, MJ
    MACKAY, B
    LUKEMAN, J
    SEMINARS IN ONCOLOGY, 1983, 10 (01) : 34 - 55
  • [4] Genes and Pathology of Non-Small Cell Lung Carcinoma
    Sakashita, Shingo
    Sakashita, Mai
    Tsao, Ming Sound
    SEMINARS IN ONCOLOGY, 2014, 41 (01) : 28 - 39
  • [5] News on molecular pathology in non-small cell lung cancer
    Lantuejoul, S.
    Mescam-Mancini, L.
    Burroni, B.
    McLeer-Florin, A.
    ONCOLOGIE, 2012, 14 (09) : 530 - 537
  • [6] Molecular Pathology of Primary Non-small Cell Lung Cancer
    Suster, David Ilan
    Mino-Kenudson, Mari
    ARCHIVES OF MEDICAL RESEARCH, 2020, 51 (08) : 784 - 798
  • [7] Updates in the molecular pathology of non-small cell lung cancer
    Paver, Elizabeth
    O'Toole, Sandra
    Cheng, Xin Min
    Mahar, Annabelle
    Cooper, Wendy A.
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2021, 38 (05) : 54 - 61
  • [8] Molecular Diagnostics in Non-Small Cell Lung Carcinoma
    Sholl, Lynette M.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 41 (03) : 386 - 399
  • [9] Surgical pathology of early stage non-small cell lung carcinoma
    Beasley, Mary Beth
    Dembitzer, Francine R.
    Flores, Raja M.
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (12) : 1 - 8
  • [10] Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
    Padinharayil, Hafiza
    Varghese, Jinsu
    John, Mithun Chacko
    Rajanikant, Golgodu Krishnamurthy
    Wilson, Cornelia M.
    Al-Yozbaki, Minnatallah
    Renu, Kaviyarasi
    Dewanjee, Saikat
    Sanyal, Rupa
    Dey, Abhijit
    Mukherjee, Anirban Goutam
    Wanjari, Uddesh Ramesh
    Gopalakrishnan, Abilash Valsala
    George, Alex
    GENES & DISEASES, 2023, 10 (03) : 960 - 989